What is the 13F Pro Quality Score for FATE?

13F Pro ranks FATE THERAPEUTICS INC (FATE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View FATE's current score at https://13fpro.ai/research/FATE (free sign-up required for the full ranking).

Which hedge funds own the most FATE stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of FATE include Redmile Group,, BlackRock,, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/FATE as soon as new 13F filings post.

Where does 13F Pro source FATE data?

All FATE THERAPEUTICS INC fundamentals and ownership data come directly from SEC EDGAR. FATE THERAPEUTICS INC files with the SEC under CIK 1434316. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is FATE in?

FATE THERAPEUTICS INC (FATE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is FATE research updated on 13F Pro?

FATE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

FATE THERAPEUTICS INC(FATE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1434316 FATE stock profile & AI dashboard →

13F Pro Quality Score

6.7/100

Rank #2,839 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

0.2/100

Profitability

1.5/100

Balance Sheet

4.3/100

Earnings Quality

30.0/100

Free Cash Flow

1.5/100

Institutional Flow

69.4/100

Revenue Scale

2.7/100

Dilution Risk

1.3/100

FATE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for FATE THERAPEUTICS INC (FATE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FATE at 6.7/100 on a 32-signal composite quality model, placing it at rank #2,839 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (0.2) and profitability (1.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), FATE THERAPEUTICS INC reports quarterly revenue of $1.3M, net income of $-31.2M, free cash flow of $-31.1M. Top institutional holders of FATE by reported 13-F value include Redmile Group,, BlackRock,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. FATE trades on the Nasdaq exchange and files with the SEC under CIK 1434316. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FATE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for FATE THERAPEUTICS INC directly from SEC EDGAR. FATE THERAPEUTICS INC's 13F Pro composite quality score has ranged between 4 and 36 since 2021, currently 6.7 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about FATE THERAPEUTICS INC

Quirks, history, and lore behind FATE — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in San Diego, California · focused on cancer immunotherapy.
2
The Numbers
A pre-revenue, cash-burning biotech — it spends heavily on R&D and relies on collaboration agreements with larger pharma partners to keep the lights on.
3
The History
Founded in the early 2010s, it went public on Nasdaq and built its entire pipeline around a single radical idea: engineer immune cells before a patient ever walks in the door.
4
The Secret
Its platform is built on induced pluripotent stem cells (iPSCs) — essentially a renewable "master copy" that can be reprogrammed into cancer-killing immune cells at industrial scale.
5
The Lore
It inked a major collaboration deal with Janssen (Johnson & Johnson's pharma arm) worth potentially over a billion dollars, betting that off-the-shelf cell therapy could replace today's bespoke CAR-T treatments.
6
The Giveaway
Its very name is a wink at its science: shaping the fate of stem cells into NK and T-cell therapies — and its ticker symbol says exactly that.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$1.3M

Net Income

Q1 2026

$-31.2M

Free Cash Flow

Q1 2026

$-31.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-51.2% YoY

$6.6MFY 2025

FY21 $55.8MFY22 $96.3MFY24 $13.6MFY25 $6.6M

Net Income

+26.8% YoY

$-136.3MFY 2025

FY21 $-212.2MFY22 $-281.7MFY24 $-186.3MFY25 $-136.3M

Operating Income

+29.8% YoY

$-147.7MFY 2025

FY21 $-217.0MFY22 $-308.4MFY24 $-210.3MFY25 $-147.7M

EPS (Diluted)

+29.9% YoY

$-1.15FY 2025

FY21 $-2.24FY22 $-2.91FY24 $-1.64FY25 $-1.15

Total Assets

-27.6% YoY

$318.9MFY 2025

FY21 $921.5MFY22 $705.6MFY24 $440.7MFY25 $318.9M

Total Debt

—FY 2025

FY21 —FY22 —FY24 —FY25 —

Op. Cash Flow

+13.7% YoY

$-106.1MFY 2025

FY21 $-162.9MFY22 $-248.2MFY24 $-122.9MFY25 $-106.1M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2019	FY 2018
Revenue	$6.6M -51.2%	$13.6M -85.8%	$96.3M +72.4%	$55.8M +422.9%	$10.7M +125.3%	$4.7M
Net Income	$-136.3M +26.8%	$-186.3M +33.9%	$-281.7M -32.8%	$-212.2M -116.2%	$-98.1M -47.4%	$-66.6M
Operating Income	$-147.7M +29.8%	$-210.3M +31.8%	$-308.4M -42.1%	$-217.0M -115.4%	$-100.7M -50.1%	$-67.1M
EPS (Diluted)	$-1.15 +29.9%	$-1.64 +43.6%	$-2.91 -29.9%	$-2.24	—	—
Total Assets	$318.9M -27.6%	$440.7M -37.5%	$705.6M -23.4%	$921.5M +204.8%	$302.3M +41.9%	$213.0M
Total Debt	—	—	—	—	—	$20.9M
Operating Cash Flow	$-106.1M +13.7%	$-122.9M +50.5%	$-248.2M -52.4%	$-162.9M -95.8%	$-83.2M -115.2%	$-38.6M

AI Insight: FATE Financial Trends

FATE is burning cash at a decelerating pace, but revenue has collapsed to near-zero while equity erodes by half since mid-2024.

• Operating cash burn improved from $32M in Q2 2024 to $23M in Q4 2025, then widened to $31M in Q1 2026.

• Net losses stabilized around $31–32M per quarter in Q4 2025 and Q1 2026, versus $38–52M in prior year.

• Revenue collapsed from $7M in Q2 2024 to $1M in Q4 2025 and Q1 2026 — a 86% decline.

⚠ Shareholder equity fell 55% from $397M (Q2 2024) to $180M (Q1 2026). Runway at current burn rate shrinking rapidly.

⚠ Operating cash burn spiked back to $31M in Q1 2026 after three quarters of improvement — potential reversal signal.

AI Insight: FATE Ratio Trends

FATE's profitability deteriorated sharply in Q1 2026, with ROE falling to −69.5% and ROIC to −73.5%, marking the worst quarter in the trailing dataset.

• ROE declined from −52.1% in Q2 2025 to −69.5% in Q1 2026, a 17.4pp deterioration over nine months.

• ROIC worsened from −56.6% in Q2 2025 to −73.5% in Q1 2026, indicating accelerating capital destruction.

• ROA fell to −43.8% in Q1 2026 from −36.7% in Q2 2025, signaling asset efficiency collapsing.

⚠ Q1 2026 marks the lowest return metrics in the dataset; monitor for sustained losses or path to breakeven.

⚠ Operating margins unavailable across all periods; underlying operational profitability opaque.

Get alerted when FATE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for FATE THERAPEUTICS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of FATE

Redmile Group, LLC
$15.4M12,872,946 sh
BlackRock, Inc.
$12.1M10,068,614 sh
VANGUARD CAPITAL MANAGEMENT LLC
$5.0M4,192,063 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$5.0M4,134,585 sh
TWO SIGMA INVESTMENTS, LP
$4.2M3,466,786 sh
JOHNSON & JOHNSON
$4.1M3,379,064 sh
AQR CAPITAL MANAGEMENT LLC
$3.6M3,001,521 sh
RENAISSANCE TECHNOLOGIES LLC
$3.6M2,974,683 sh
GEODE CAPITAL MANAGEMENT, LLC
$3.1M2,590,429 sh
STATE STREET CORP
$2.7M2,263,173 sh

Fund	Value	Shares
Redmile Group, LLC	$15.4M	12,872,946
BlackRock, Inc.	$12.1M	10,068,614
VANGUARD CAPITAL MANAGEMENT LLC	$5.0M	4,192,063
VANGUARD PORTFOLIO MANAGEMENT LLC	$5.0M	4,134,585
TWO SIGMA INVESTMENTS, LP	$4.2M	3,466,786
JOHNSON & JOHNSON	$4.1M	3,379,064
AQR CAPITAL MANAGEMENT LLC	$3.6M	3,001,521
RENAISSANCE TECHNOLOGIES LLC	$3.6M	2,974,683
GEODE CAPITAL MANAGEMENT, LLC	$3.1M	2,590,429
STATE STREET CORP	$2.7M	2,263,173

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put FATE on your watchlist

Track score changes the day FATE THERAPEUTICS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is FATE a good stock to buy?

13F Pro's AI-powered analysis of FATE THERAPEUTICS INC (FATE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FATE are available on the FATE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own FATE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FATE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of FATE THERAPEUTICS INC's investment landscape.